Increase in IL-15 levels in patients with alopecia areata
DOI:
https://doi.org/10.12775/JEHS.2020.10.09.008Keywords
alopecia areata, IL-15, immunologyAbstract
Introduction and purpose: Alopecia areata (AA) is a condition that causes non-scarring hair loss (often with acute onset). Alopecia areata in the population occurs in 0.1-0.2% of people, with a similar frequency in men and women. Alopecia areata is an example of an autoimmune disease of the hair follicle. Hair loss in alopecia areata is caused by lymphocytic infiltration around the hair follicle and IFN-γ. IgG antibodies against hair follicle cells are also found in people suffering from alopecia areata. Recent studies have shown a significant increase in IL-15 in AA. The aim of the study was to review the current knowledge on the use of IL-15 in the treatment of alopecia areata.
A brief description of the state of knowledge: Interleukin-15 (IL-15) is a pleiotropic cytokine that exhibits multidirectional biological effects on various cell types. It affects the functions of the immune system, both innate and acquired, and therefore plays an important role in inflammation and during the immune response to infections and infestations. In the AA mouse model, antibody-mediated blockade of IFN-γ, interleukin-2 (IL-2), or interleukin-15 receptor β (IL-15Rβ) prevented disease progression by minimizing the accumulation of CD8 (+) NKG2D (+) T cells in the skin and reducing the cutaneous IFN response. The concentration of IL-15 in patients with alopecia areata was significantly higher than in the control group. Moreover, the concentration of IL-15 increased in direct proportion to the area of alopecia, the highest value in patients with total alopecia.
For this reason, it is important to search for new medical treatments that will enable patients to stay physically healthy, and what is equally important, to remain mental health.
Conclusions: In addition, studies have shown an increase in IL-15 levels in patients with alopecia areata, which correlated with the duration of the disease. However, too few studies conducted so far do not allow conclusions to be drawn regarding the use of IL-15 as a therapeutic point.
References
Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM (2007) Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 80:316–328.
Finner am. alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol ther 2011;24:348-54.
Slowinska m, Kardynal a, Warszawik o, Czuwara J, rudnickal: alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy. J Dermatol Case rep 2010,4: 15-17.
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515-1525.
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. (1995) Częstość występowania łysienia plackowatego w Olmsted County, Minnesota, 1975 do 1989. Mayo Clin Proc 70 (7): 628–633.
Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E (2009) Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol 23 (5): 572–573
Trüeb, R.M., Dias, M.F.R.G. Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. Clinic Rev Allerg Immunol 54, 68–87 (2018).
Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. J Autoimmun. 2019;98:74-85.
Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.
Titeca G, Goudetsidis L, Francq B, et al. 'The psychosocial burden of alopecia areata and androgenetica': a cross-sectional multicentre study among dermatological out-patients in 13 European countries [published correction appears in J Eur Acad Dermatol Venereol. 2020 May;34(5):1119]. J Eur Acad Dermatol Venereol. 2020;34(2):406-411.
Güleç AT, Tanriverdi N, Dürü C, Saray Y, Akçali C. The role of psychological factors in alopecia areata and the impact of the disease on the quality of life. Int J Dermatol. 2004;43(5):352-356.
Alopecia areata: psychiatric comorbidity and adjustment to illness.
Ruiz-Doblado S, Carrizosa A, García-Hernández MJ Int J Dermatol. 2003 Jun; 42(6):434-7.
Ruiz-Doblado S, Carrizosa A, García-Hernández MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. International Journal of Dermatology. 2003;42(6):434–437.
Grahovac T, Ružić K, Šepić-Grahovac D, Dadić-Hero E, Pavešić Radonja A. Depressive disorder and alopecia. Psychiatria Danubina. 2010;22(2):293–295.
Ataseven A, Saral Y, Godekmerdan A. Serum cytokine levels and anxiety and depression rates in patients with Alopecia areata. Eurasian Journal of Medicine. 2011;43(2):99–102.
Koblenzer CS. Psychocutaneous Disease. Orlando, Fla, USA: Grune & Stratton; 1987.
Arnold LM. Psychogenic excoriation: clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs. 2001;15(5):351–359.
Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata. Ghajarzadeh M, Ghiasi M, Kheirkhah S Acta Med Iran. 2012; 50(7):511-5.
Psychological status of patients with alopecia areata. Alfani S, Antinone V, Mozzetta A, Di Pietro C, Mazzanti C, Stella P, Raskovich D, Abeni D Acta Derm Venereol. 2012 May; 92(3):304-6.
Layegh P, Arshadi H, Shahriari S, Pezeshkpour F, Nahidi Y. A comparative study on the prevalence of depression and suicidal ideation in dermatology patients suffering from Psoriasis, Acne, Alopecia areata and Vitiligo. Iranian Journal of Dermatology. 2010;13:106–111.
Arbabi N, Salami F, Forouzesh F, Gharehbeglou M, Riyahin A, Shahrzad M. Effects of stress and stressful events on Alopecia areata. Life Science Journal. 2013;10(6)
Hypnosis and alopecia areata: Long-term beneficial effects on psychological well-being. Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J Acta Derm Venereol. 2011 Jan; 91(1):35-9.
Hypnotic approaches for alopecia areata. Willemsen R, Vanderlinden J Int J Clin Exp Hypn. 2008 Jul; 56(3):318-33.
Aghaei S, Saki N, Daneshmand E, Kardeh B. Prevalence of psychological disorders in patients with alopecia areata in comparison with normal subjects. ISRN Dermatol. 2014 Mar 9;2014:304370.
Holter RF, Bargoon C. Psychological consideration of the skin in childhood. Pediatric Clinics of North America. 1961;8:719–739.
Holter RF, Bargoon C. Pediatric Clinics of North America. 1961;8:719–739.
Dermatopsychosomatics: classification, physiology, and therapeutic approaches. Medansky RS, Handler RM J Am Acad Dermatol. 1981 Aug; 5(2):125-36.
Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: An Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163-170.
França K, Castillo D, Tchernev G, Lotti T. UVA-1 in the treatment of alopecia areata. Dermatol Ther. 2017;30(6):10.1111/dth.12547.
Morsy H, Maher R, Negm D. Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy. J Cosmet Dermatol. 2018;17(3):533-537.
Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: Implications for its therapeutic use. Microbes Infect. 2012;14:247–61.
Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043–9.
Marçais A, Cherfils-Vicini J, Viant C, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014;15:749–57.
Fuentes-Duculan J, Gulati N, Bonifacio KM, Kunjravia N, Zheng X, Suárez-Fariñas M, Shemer A, Guttman-Yassky E, Krueger JG. Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol. 2015.
Fuentes-Duculan J, Gulati N, Bonifacio KM, et al. Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. Exp Dermatol. 2016;25(4):282-286.
Ebrahim AA, Salem RM, El Fallah AA, Younis ET. Serum Interleukin-15 is a Marker of Alopecia Areata Severity. Int J Trichology. 2019;11(1):26-30.
Tabara K, Kozłowska M, Jędrowiak A, Bienias W, Kaszuba A. Serum concentrations of selected proinflammatory cytokines in children with alopecia areata. Postepy Dermatol Alergol. 2019;36(1):63-69.
Bansal A, Relhan V, Garg VK, Saran RK. A cross-sectional study of the histopathology and immunology of alopecia areata: Unearthing the role of the Janus kinase-signal transducer and activator of transcription pathway. Indian J Dermatol Venereol Leprol. 2019;85(5):455-461.
Kim JE, Lee YJ, Park HR, Lee DG, Jeong KH, Kang H. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells. Int J Mol Sci. 2020;21(14):5137.
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736-744.
Almutairi N, Nour TM, Hussain NH. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Dermatology. 2019;235(2):130-136.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 874
Number of citations: 0
